The First NOVAST Approval by China NMPA- Metformin Hydrochloride Sustained-release Tablets (III)

On October 9, 2021, NOVAST received our FIRST Approval notice from China NMPA. In accordance with the relevant provisions of the Drug Administration Law, Metformin Hydrochloride Sustained-release Tablets (III )（1.0g）developed by NOVAST was approved by China NMPA, which marked the FIRST breakthrough of NMPA product approval for NOVAST.